More information: Reut Shor et al, Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.1455 ...

Send comments and news tips to news@medscape.net. Cite this: Edited by Shrabasti Bhattacharya. Intensive Bevacizumab Boosts Vision in Macular Degeneration - Medscape - June 19, 2025.

Depending upon the type of glaucoma, you may or may not even have symptoms. The most common type is primary open-angle glaucoma. It has no noticeable signs except gradual vision loss.

Glaucoma is a vision problem that begins without pain and ends in blindness. Don’t wait for symptoms and check out these tips to catch it before it’s too late.

Founder Group has entered a memorandum of understanding (MoU) with GCL Systems Integration Technology to develop renewable energy projects across Malaysia and other ASEAN countries, with potential ...

Asif M, Asif A, Rahman UA, et al. Incidence of glaucoma in type 2 diabetes patients treated with GLP-1 receptor agonists: a systematic review and meta-analysis. 2025;8:e70059. doi:10.1002/edm2 ...

Macular edema is swelling of the macula due to leaking fluid from blood vessels. It does not cause severe symptoms at first but can eventually lead to blurry and worsening vision, especially at ...

Source Reference: Shor R, et al "Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration" JAMA Ophthalmol 2025; DOI: 10.1001/jamaophthalmol.2025.1455.

A high-level overview of GCL Global Holdings Ltd (GCL) stock. View (GCL) real-time stock price, chart, news, analysis, analyst reviews and more.

DOI: 10.1093/pnasnexus/pgaf168 Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by high pressure inside the eye.

Key Insights Significantly high institutional ownership implies RF Acquisition Corp II's stock price is sensitive to... As of 6.00 p.m. (Singapore time) on June 12, 2025, GCL’s indirect ...

GCL Announces Close of Subsidiary’s Offer for Ban Leong Technologies Limited with Compulsory Acquisition and Delisting to follow As of 5:30 p.m. (Singapore time) on July 02, 2025, the offer has closed ...